Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.

Authors :: Fleming GF
Pagani O
Regan MM
Walley BA
Francis PA
Source :: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Jun; Vol. 33 (6), pp. 658. Date of Electronic Publication: 2022 Mar 14.
Publication Year :: 2022
Abstract: Competing Interests: Disclosure MMR reports funding from Pfizer for palbociclib trials at IBCSG and DFCI. The remaining authors declare no conflict of interest relevant to this letter.

Subjects :: Aminopyridines
Antineoplastic Combined Chemotherapy Protocols adverse effects
Benzimidazoles therapeutic use
Female
Humans
Ki-67 Antigen
Receptor, ErbB-2
Breast Neoplasms drug therapy

Language :: English
ISSN :: 1569-8041
Volume :: 33
Issue :: 6
Database :: MEDLINE
Journal :: Annals of oncology : official journal of the European Society for Medical Oncology
Publication Type :: Editorial & Opinion
Accession number :: 35301096
Full Text :: https://doi.org/10.1016/j.annonc.2022.03.003

Full Text Access

Tools